community protocols describe rotating injection sites between doses
Physiological adaptations to weight loss and factors favouring weight regain
In pediatric patients with open epiphyses, treatment with EGRIFTA WR may result in linear growth acceleration and excessive growth
Altered serum levels of vascular endothelial growth factor in first-episode drug-nave and chronic medicated schizophrenia
Xing F, Liu Y, Wu SY, Wu K, Sharma S, Mo YY, et al
Use immediately after preparation Duration of therapy: Varies by condition (weeks to several months) Contraindications Known hypersensitivity to glutathione or any formulation component Use in pregnancy or breastfeeding without medical supervision History of severe allergic reactions to similar substances Precautions and Warnings Caution in renal impairment due to risk of accumulation Monitor liver function tests regularly Do not use as monotherapy in severe disease states Asthmatic patients may be at risk of bronchospasm Off-label use (e.g., skin whitening) requires medical oversight Adverse Effects Local reactions: Pain, swelling, redness at injection site Allergic reactions: Rash, itching, rarely anaphylaxis Respiratory: Mild bronchospasm (rare) Neurological: Headache or dizziness (rare) Drug Interactions May potentiate effects of certain chemotherapeutic agents consult oncology specialist No significant interactions known, but always disclose all medications to the healthcare provider Pregnancy and Lactation Use only under medical advice if pregnant or breastfeeding
